Latest From Altacor Ltd.
Proposed acquisition mimics other recent M&A deals, like Sanofi/Genzyme, with inclusion of contingent-value rights pegged to success of two clinical candidates.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Valeant buys into Russian OTC market; NicOx buys stake in U.K. ophthalmology firm Altacor; Naturex reaches India coverage; Eurofins purchases BASF test business; Fortitech fortifies Asian presence; more news In Brief.
This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
- OTC, Consumer
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Altacor Ltd.
- Senior Management
Fran Crawford, CEO
Rob Sprawson, CFO
David Alcraft, Dir., Bus. Dev.
Andy Baxter, Head, Product Development
Gareth Thomas, Head, Sales & Mktg.
- Contact Info
Phone: (44) 1223 421 411
St. John's Innovation Centre
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.